Published April 9, 2026 | Version v1

Finerenone in patients with type 2 diabetes mellitus and diabetic kidney disease: A retrospective clinical study

  • 1. Department of Nephrology, Medical University of Plovdiv, St George University Hospital, Plovdiv, Bulgaria
  • 2. Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, Plovdiv, Bulgaria|Clinic of Cardiology, St. George University Hospital, Plovdiv, Bulgaria
  • 3. Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria
  • 4. Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, Plovdiv, Bulgaria|Research Institute at Medical University of Plovdiv, Medical University of Plovdiv, Plovdiv, Bulgaria|Department of Nephrology, Medical University of Plovdiv, St George University Hospital, Plovdiv, Bulgaria
  • 5. Deparment of Healthcare Management, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria

Description

Background: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease progression and increased cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Despite optimized standard therapy, substantial residual renal risk persists. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated cardiorenal benefits in large randomized clinical trials.

Materials and methods: This single-center retrospective observational study included 82 adult patients with T2DM and DKD treated with finerenone as add-on therapy to standard care. Renal parameters—including serum creatinine, estimated glomerular filtration rate (eGFR), microalbuminuria, urine albumin-to-creatinine ratio (UACR), and serum potassium—were evaluated at baseline and after 6–12 months of therapy. Data are presented as mean ± SD. A paired student's t-test or Wilcoxon test was used as appropriate, with p < 0.05 considered statistically significant.

Results: Mean age was 68.1 ± 10.2 years, and 54.9% of patients were women. After therapy, serum creatinine increased modestly (Δ +2.9%, p < 0.001), while eGFR declined slightly (Δ −4.4%, p < 0.001). Significant reductions were observed in microalbuminuria (Δ −16.6%, p < 0.001) and UACR (Δ −21.0%, p < 0.001). Serum potassium increased (Δ +9.5%, p < 0.001), remaining within clinically acceptable limits. Subgroup analysis demonstrated significant UACR reduction across different albuminuria categories.

Conclusion: In patients with T2DM and DKD, finerenone therapy was associated with significant reductions in albuminuria and modest changes in renal function parameters during routine follow-up. These findings are consistent with data from randomized clinical trials and support the role of finerenone as part of a comprehensive therapeutic approach in albuminuric DKD.

Files

PHAR_article_188831.pdf

Files (295.7 kB)

Name Size
md5:b8ebcf6bff811fc3723d53bdca3bd819
246.2 kB Preview Download
md5:341b6456d01b8d8e0a2122fd987455de
49.4 kB Preview Download

Additional details

References